page full analyst note may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim apr
price data may
rate updat may
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
remain one largest gener drug manufactur
thank on-going acquisit compel gener launch
advair restasi regardless still long-term concern
hefti price pressur gener industri firm
capit larg valu drug come patent
past year see increas challeng ahead
think recent sluggish industri growth continu due fewer
larg drug patent expir consolid custom base
unit state entri nimbl low-cost competitor
acquisit agila meda abbott non-u
increas product
geograph diversif competit dynam
govern price continu limit organ growth
opportun europ well
follow similar strategi peer intend overcom
gener industri concern expand specialti pharma
complex gener oper complex gener
biosimilar inject respiratori inhal gener face
limit competit enjoy higher margin thank higher
develop manufactur regulatori hurdl
develop biosimilar gener insulin partner like
biocon far compani secur approv
gener version glaxosmithklin advair despit
win still skeptic success
complex product think compani trail
peer biosimilar
specialti drug segment made primarili epipen
grown expect emerg compet
epinephrin product pressur segment futur growth
profit follow recent critic price increas
manag launch author epipen gener late
follow launch teva gener copi late beyond
epipen compani mostli lack pipelin brand drug
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
one world largest gener pharmaceut manufactur
oper unit state europ asia middl east africa
australia gener drug sale constitut approxim revenu
remain sale come hand brand product primarili
epinephrin injector epipen also own matrix indian activ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
normal ep came slightli expect
overal revenu soft larg driven lower-than-
expect volum partial due time issu advers
foreign currenc exchang rate lesser degre
price competit pressur appear let
includ uptak challeng due payor prefer
brand drug despit re-affirmed guidanc time
new product launch share intra-day due
manag re-affirmed full-year revenu earn
free cash flow guidanc billion billion
billion billion respect
maintain no-moat rate fair valu estim
skeptic
back-end
manag indic necessari approv
grant help pave way toward billion
new product revenu target fiscal million
record first quarter new product
revenu target consist product launch carryov
launch wixela gener form respiratori drug
advair launch first quarter new product
launch occur throughout year net debt tick
due recent product
invest
manag confirm track achiev
leverag ratio time year-end fiscal first
quarter revenu declin year year billion
normal ep declin year year
normal ebitda margin declin last
although encourag progress new
product launch overal manag tone seem
cautiou still would exercis caution name
mani move part concern
back-end load guidanc
maintain fair valu estim per share
earn multipl approxim reflect
compani growth challeng gener drug industri
epipen competit headwind
despit temporari bump launch gener
advair estim low-single-digit compound annual
organ sale growth gener segment
intern market growth help off-set minim
european market growth see limit growth
specialti brand sale thank recent
teva late although advanc
biosimilar product clinic trial made us
optimist approv product remain
somewhat skeptic complex biosimilar like
humira addit gener insulin product like lantu
estim modest sale biosimilar near term
compani ramp market effort
model long-term margin compress epipen sale
erod aggress competit gener industri
persist near term also face higher oper
cost market complex product correct
action regulatori issu greater economi
scale realiz acquisit synergi potenti
launch specialti product like gener advair
offer stabil profit therefor forecast
adjust ebitda margin near continu
declin low rang long term also
project tax rate high teen thank tax
invers acquir abbott asset on-going
intern expans recent tax legisl
 return capit remain model
peg compani cost capit approxim
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fair valu estim per share
bear-cas scenario gener segment forecast
incorpor greater price eros market along
low- mid-single-digit growth european
steeper market-shar loss epipen addit lower
market-shar gain biosimilar respiratori
inhal insulin along nearli flat revenu
growth project price pressur lead ebitda
margin fall rang longer term
bear-cas scenario share worth
think possess econom moat
consid gener drug industri whole
predominantli no-moat industri barrier entri remain
low product remain highli commodit industri
previous thought global economi scale
vertic integr help give firm low-cost edg
think continu rise new entrant particularli
low-cost emerg market continu diminish cost
advantag larger peer addit believ
mylan first-to-fil pipelin manufactur capabl
complex product help differenti firm
heavili commodit aspect
industri diminish confid lead
sustain econom profit long term
abil challeng gradual improv lack larg
number product go patent increas gener
util rate seen past decad probabl mean
growth margin expans firm past
difficult sustain
possess fairli larg pipelin complex
gener product includ version insulin
biosimilar despit recent success product like
advair copaxon remain skeptic mylan
give mylan high uncertainti rate due
rel high geograph product concentr
addit pipelin unpredict gener
product includ gener form advair lantu
biosimilar better-than-expect success number
complex product launch could caus
outperform expect howev
bull-cas scenario model high-single-digit growth
asia-pacif revenu mid-single-digit growth north
american european revenu lead organ
five-year compound growth rate gener
product revenu growth less-competit market share
loss price pressur epipen combin faster
market share gain biosimilar respiratori
pressur patent cliff greater biosimilar
launch success achiev
better-than-expect restructur effort manufactur
scale forecast ebitda margin near fall
long term bull-cas scenario result
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
success product given high
manufactur regulatori market hurdl even
receiv approv biosimilar like need
hefti market effort product sinc
adept biopharma firm enter space
particularli novarti
mylan specialti drug franchis also benefit patent
protect drive consider profit key
franchis essenti compos entir epipen
creat sustain competit advantag due
compani heavi concentr product epipen
previous repres larg portion busi
sale profit estim
although epipen face limit gener competit
begin late teva addit author
gener thank manufactur complex brand
recognit uniqu product still imagin price
pressur depress drug momentum meanwhil
major brand product pipelin
think neg econom moat trend
think rel larg exposur
europ gener drug market threaten erod firm
cost advantag time addit recent gener
competit epipen diminish
price power also skeptic eventu success
certain pipelin product includ biosimilar
gener advair success launch product
could caus us re-evalu long-term assumpt
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
one world largest gener industri player
enjoy economi scale smaller
ocompar peer less diversifi
oper increas exposur volatil gener
oth acquisit agila meda boost
inject over-the-counter drug product
sustain steadier growth profit thank
limit competit market segment
face consider competit low-cost
develop complex gener drug
includ biosimilar gener version advair
copaxon
earn growth approv
competit teva gener version
product launch
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
appetit acquisit drive growth prospect
probabl keep financi leverag rel high mylan
use consider debt purchas matrix merck
kgaa gener subsidiari respect
result compani financi leverag although
manag stood consider higher
gener competitor manag done good job
year boost growth profit
help eas debt repay concern moreov
all-stock acquisit abbott non-u developed-market
asset help de-lever compani
purchas meda late increas financi
leverag end net debt/ebitda ratio
approxim time estim
modestli declin thank recent gener
advair launch potenti product approv
regardless think long-term debt/ebitda ratio
repres realist long-term averag given
give mylan high uncertainti rate due
volatil gener drug industri rel
high financi leverag furthermor rel
high geograph product concentr addit
pipelin unpredict gener product includ
gener form advair lantu biosimilar mylan
histori aggress acquisit less diversifi
oper pipelin uncertain product like gener
advair insulin make higher-risk oper
peer view sizabl global
footprint still consider exposur gener
drug market eventu declin valu
drug come patent could spell troubl addit
even close abbott meda deal signific
portion oper remain center
western europ face stiff price pressur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
year also lack sizabl brand drug segment
innov pipelin epipen franchis face
gener competit teva past critic
price increas epipen spur manag offer
access program author gener
previous diminish sale manag also settl
 depart justic million
critic epipen classif gener product
medicaid rebat program bold pipelin
biosimilar insulin off-set competit
epipen think uncertainti success
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
share
fund
share
fund
think averag stewardship practic
effect capit alloc mix view
mani manag strateg initi past
year bolster compani oper
includ scale vertic integr manufactur
capabl hard-to-manufactur product howev
think high take-over multipl larg amount financi
leverag slow integr process acquir
busi hamper potenti sharehold return
declin high geograph concentr
southern region contin
particularli affect auster measur although mylan
gain greater diversif scale lower tax rate
acquisit abbott developed-market asset
follow purchas meda still concern
growth prospect europ follow
deal addit high-stak acquisit
inject manufactur agila becam cloud
compani receiv food drug administr
warn letter manufactur qualiti concern
critic price increas epipen led neg media
attent settlement depart
justic improp classif drug
compar peer consid execut pay
significantli averag includ person aircraft
use company-provid automobil larg portion
execut compens tie adjust earn per
share good measur long-term valu
creation view also skeptic manag
past use aggress long-term guidanc either
assum approv compani complex
pipelin product took optimist acquisit outlook
perspect
heather bresch compani nearli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
year becam ceo earli robert couri
ceo sinc transit execut chairman
bresch couri presid rajiv malik retir harri
korman repres four compani insid
board multist civil investig potenti price
collus among gener manufactur target malik
remain execut board role time
parrish replac rodney piatt lead independ
director vice chairman board parrish
board member sinc current chairman
ceo trident provid mobil x-ray laboratori
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
stabil gener market
imagin mani factor stay persist
headwind addit complex
gener launch help uphold sale gross margin
becom expens endeavor sell
product market share gain slow
adjust ep rel flat year
manag outlook year suggest
earn declin midpoint
place review transfer coverag
new analyst expect publish new fair valu
estim second quarter
post disappoint fourth quarter
plan lower fair valu estim
perform although number recent product launch
like fulphila biosimilar neulasta wixela gener
advair help keep forecast billion revenu
year near midpoint guidanc adjust
ep estim fall high end manag
goal although expect
margin pressur gener competit epipen
on-going price pressur
 market
manag see higher market expens
anticip part sell effort
necessari compani complex product well
higher tax rate specul part higher cost
also stem warn letter receiv fourth
quarter morgantown manufactur facil
decent success beat competitor
market complex gener product includ
product like gener copaxon challeng reinforc
no-moat rate compani peer
mylan fourth-quart revenu declin year
ago stem declin north america
revenu off-set posit growth intern market
share gain gener copaxon late approv
gener advair morgantown remedi issu
ration gener portfolio amid competit
price pressur anticip price
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
